Clinical trial · Observational
HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this registry study the investigators will collect data about patients' disease, treatment, and response to treatment to include in both our local and national databases. These can then be used by investigators to answer questions about cytoreductive surgery/HIPEC such as how well-tolerated or effective it is in specific populations.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Neoplasm Metastasis | — | UNRESOLVED | — |
| Peritoneal Neoplasms | Peritoneal Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- From time of treatment until death, approximately 10 years
- description
- Collect data from patients undergoing CRS/HIPEC which will be used to examine overall survival rates in specific patient populations.
Secondary outcomes (2)
- measure
- Progression-free survival rate
- timeFrame
- From time of treatment until time of disease progression, approximately 10 years
- description
- Collect data from patients undergoing CRS/HIPEC which will be used to examine progression-free survival rates in specific patient populations
- measure
- Rates of complications
- timeFrame
- During procedure until approximately 90 days post
- description
- Collect data from patients to examine rates of complications in specific patient populations
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Eligible to undergo cytoreductive surgery followed by HIPEC performed by the PI at Edward Hospital * Provides consent by signing informed consent form Exclusion Criteria: * Not eligible for surgery or for potential cytoreductive surgery and/or HIPEC as determined by the PI * Does not consent to participate
References
Publications (0)
Data not yet available